Skip to main content
SpringerLink
Log in

Allogeneic Hematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders

  • Chapter
Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment (Review). Mayo Clin. Proc. 2006; 81:104–130.

    Article  PubMed  Google Scholar 

  2. Campbell PJ, Green AR. The myeloproliferative disorders (Review). N.Engl. J.Med. 2006; 355:2452–2466.

    Article  PubMed  CAS  Google Scholar 

  3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 434:1144–1148.

    Article  PubMed  CAS  Google Scholar 

  4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005; 352:1779–1790.

    Article  PubMed  CAS  Google Scholar 

  5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982; 51:189–199.

    PubMed  CAS  Google Scholar 

  6. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hemat-opoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999; 17:3835–3849.

    PubMed  CAS  Google Scholar 

  7. Scott B, Deeg HJ. Hemopoietic cell transplantation as curative therapy of myelo-dysplastic syndromes and myeloproliferative disorders. Best Practice & Research Clinical Haematology 2006; 19:519–522.

    Article  Google Scholar 

  8. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood 1998 Feb 1;91(3):1100). Blood 1997; 89:2079–2088.

    PubMed  CAS  Google Scholar 

  9. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Invernizzi R, Giagounidis A, et al. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood 2005; 106:232a–233a. Abstract.

    Google Scholar 

  10. , Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013–1018.

    PubMed  CAS  Google Scholar 

  11. Dingli D, Schwager SM, Mesa RA, Li C Y, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2006; 106:623–630.

    Article  PubMed  Google Scholar 

  12. Kerbauy DMB, Gooley TA, Sale GE, Flowers MED, Doney KC, Georges GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. In press.

    Google Scholar 

  13. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98:3249–3255.

    Article  PubMed  CAS  Google Scholar 

  14. Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br. J. Haematol. 2005; 128:42–48.

    Article  PubMed  Google Scholar 

  15. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 2001; 113:763–771.

    Article  PubMed  CAS  Google Scholar 

  16. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99:840–849.

    Article  PubMed  CAS  Google Scholar 

  17. Deeg HJ. Transplant strategies for patients with myelodysplastic syndromes. Curr. Opin. Hematol. 2006; 13:61–66.

    Article  PubMed  Google Scholar 

  18. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912–2919.

    Article  PubMed  CAS  Google Scholar 

  19. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104:579–585.

    Article  PubMed  CAS  Google Scholar 

  20. Deeg HJ, Gooley TA, Flowers MED, Sale GE, Slattery JT, Anasetti C, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102:3912–3918.

    Article  PubMed  CAS  Google Scholar 

  21. Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99:4370–4378.

    Article  PubMed  CAS  Google Scholar 

  22. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodys-plastic syndrome. Blood 2002; 100:1201–1207.

    Article  PubMed  CAS  Google Scholar 

  23. Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K, et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101:4711–4713.

    Article  PubMed  CAS  Google Scholar 

  24. Ooi J. The efficacy of unrelated cord blood transplantation for adult myelodysplas-tic syndrome. Leuk. Lymphoma 2006; 47:599–602.

    Article  PubMed  Google Scholar 

  25. Koh LP, Chao NJ. Umbilical cord blood transplantation in adults using myeloab-lative and nonmyeloablative preparative regimens (Review). Biol Blood Marrow Transplant 2004; 10:1–22.

    Article  PubMed  Google Scholar 

  26. Barker JN, Weisdorf DJ, Defor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343–1347.

    Article  PubMed  CAS  Google Scholar 

  27. Petersdorf EW, Malkki M. Human leukocyte antigen matching in unrelated donor hematopoietic cell transplantation. Semin. Hematol. 2005; 42:76–84.

    Article  PubMed  CAS  Google Scholar 

  28. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004; 104:1923–1930.

    Article  PubMed  CAS  Google Scholar 

  29. Maris M, Storb R. The transplantation of hematopoietic stem cells after non-myelo-ablative conditioning: A cellular therapeutic approach to hematologic and genetic diseases. Immunologic Research 2003; 28:13–24.

    Article  PubMed  Google Scholar 

  30. Platzbecker U, Ehninger G, Schmitz N, Bornhäuser M. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases (Review). Ann. Hematol. 2003; 82:463–468.

    Article  PubMed  CAS  Google Scholar 

  31. Maris MB, Sandmaier BM, Storer B, Shizuru J, Maloney D, Agura E, et al. Unrelated donor peripheral blood stem cell (PBSC) transplantation using nonmy-eloablative conditioning and mycophenolate mofetil (MMF) TID results in high engraftment rates. Blood 2004; 104 (Part 1):503a, #1818. Abstract.

    Google Scholar 

  32. Yakoub-Agha I, de La Salmonière P, Ribaud P, Sutton L, Wattel E, Kuentz M, et al. Allogeneic bone marrow transplantation for therapy-related myelodsyplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation. J.Clin.Oncol. 2000; 18:963–971.

    PubMed  CAS  Google Scholar 

  33. Scott BL, Storer B, Loken M, Storb R, Appelbaum FR, Deeg HJ. Pre-transplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11:65–73.

    Article  PubMed  Google Scholar 

  34. Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998; 21:255–261.

    Article  PubMed  CAS  Google Scholar 

  35. Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant. 1998; 21:1213–1216.

    Article  PubMed  CAS  Google Scholar 

  36. Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100:1997–2004.

    PubMed  CAS  Google Scholar 

  37. Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99:1943–1951.

    Article  PubMed  CAS  Google Scholar 

  38. Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 2002; 8:161–169.

    Article  PubMed  Google Scholar 

  39. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J. Clin. Oncol. 1996; 14:220–226.

    PubMed  CAS  Google Scholar 

  40. Bornhäuser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of alloge-neic hematopoietic stem cells. Blood 2003; 102:820–826.

    Article  PubMed  Google Scholar 

  41. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104:857–864.

    Article  PubMed  Google Scholar 

  42. Singhal S, Powles R, Treleaven J, Pollard C, Lumley H, Mehta J. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant. 1995; 16:743–746.

    PubMed  CAS  Google Scholar 

  43. Guardiola P, Esperou H, Cazals-Hatem D, Ifrah N, Jouet J-P, Buzyn A, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br. J. Haematol. 1997; 98:1004–1009.

    Article  PubMed  CAS  Google Scholar 

  44. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to poly-cythaemia vera or essential thrombocytosis. Br.J.Haematol. 1997; 98:1010–1016.

    Article  PubMed  CAS  Google Scholar 

  45. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases (Review). Am. J. Hematol. 1998; 57:24–28.

    Article  PubMed  CAS  Google Scholar 

  46. van Besien K, Deeg HJ. Hematopoietic stem cell transplantation for myelofibrosis. Semin. Oncol. 2005; 32:414–421.

    Article  PubMed  Google Scholar 

  47. Sale GE, Deeg HJ, Porter BA. Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant 2006; 12:1285–1294.

    Article  PubMed  Google Scholar 

  48. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Société Fran栩se de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 1999; 93:2831–2838.

    PubMed  CAS  Google Scholar 

  49. Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, van Biezen A, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br. J. Haematol. 2002; 118:67–73.

    Article  PubMed  Google Scholar 

  50. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006; 37:1003–1008.

    Article  PubMed  CAS  Google Scholar 

  51. Kerbauy DMB, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005; 11:713–720.

    Article  PubMed  Google Scholar 

  52. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756–763.

    PubMed  CAS  Google Scholar 

  53. Stuart MJ, Cao TM, Sandmaier BM, Hegenbart U, Maris M, Agura E, et al. Efficacy of non-myeloablative allogeneic transplant for patients with myelodys-plastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia). Blood 2003; 102 (Part 1):185a, #644. Abstract.

    Google Scholar 

  54. Deeg HJ, Maris MB, Scott BL, Warren EH. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 2006; 20:1701–1705.

    Article  PubMed  CAS  Google Scholar 

  55. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann. Hematol. 2003; 82:336–342.

    Article  PubMed  CAS  Google Scholar 

  56. Martino R, Caballero MD, Simón JA, Canals C, Solano C, Urbano-Ispízua A, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100:2243–2245.

    Article  PubMed  CAS  Google Scholar 

  57. Lim ZY, Ho AY, Ingram W, Kenyon M, Pearce L, Czepulkowski B, et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br. J. Haematol. 2006; 135:201–209.

    Article  PubMed  Google Scholar 

  58. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 2005; 23:5728–5738.

    Article  PubMed  Google Scholar 

  59. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99:2255–2258.

    Article  PubMed  CAS  Google Scholar 

  60. Snyder DS, Palmer J, Stein AS, Pullarkat V, Sahebi F, Cohen S, et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006; 12:1161–1168.

    Article  PubMed  Google Scholar 

  61. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105:4115–4119.

    Article  PubMed  CAS  Google Scholar 

  62. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dys-plasia: a retrospective analysis. Leukemia 2006; 20:128–135.

    Article  PubMed  CAS  Google Scholar 

  63. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12:1047–1055.

    Article  PubMed  Google Scholar 

  64. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108:836–846.

    Article  PubMed  CAS  Google Scholar 

  65. Mohty M, Nagler A, Killmann NM. Reduced-intensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink? Leukemia 2006; 20:1653–1654.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Joanne Greene for maintaining the MDS/MPD database, and Bonnie Larson and Helen Crawford for help with manuscript preparation.

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

    Aravind Ramakrishnan

  2. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA

    H. Joachim Deeg

Authors
  1. Aravind Ramakrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Joachim Deeg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ramakrishnan, A., Deeg, H.J. (2008). Allogeneic Hematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_9

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation